Stocks to buy

Although we constantly receive conflicting messaging, we continue to be in the midst of a global economic recovery. That recovery translates to an opportunity for infrastructure stocks as building ramps up. Current expectations are that 2023 will result in 2.8% growth in the construction sector globally, with 3% growth expected next year. Inflation rates worldwide will
0 Comments
Every now and then, the stock market overreacts. Investors sell stocks because of fear, and solid businesses are mispriced. Savvy investors take advantage. For example, Warren Buffett’s net worth has grown to over $100 billion by purchasing mispriced stocks and waiting. Also, he is seemingly a fan of bank stocks. Buffett’s investment vehicle, Berkshire Hathaway
0 Comments
Buying dividend aristocrats is a reasonable strategy for those investors seeking long-term income. The equities in this group have paid increasing dividends for the past 25+ years, so they will likely continue to provide passive income for the foreseeable future. It’s a pretty select group, consisting of 68 publicly traded companies, all of which are
0 Comments
Electric vehicle (EV) manufacturer Mullen Automotive (NASDAQ:MULN) has a new majority-owned subsidiary that was formed through a joint venture. Already, Mullen Automotive has made a couple of positive announcements regarding that subsidiary. Therefore, the extreme drawdown in MULN stock looks overdone, and it’s a good time to start a share position in Mullen Automotive. It’s
0 Comments
In the current polarized geopolitical landscape, there is much apprehension between China and US-led factions. This simmering mistrust has triggered a race for technology and military superiority. Consequently, cyber warfare has emerged as a major frontier for this contest. This article highlights the best cybersecurity stocks to buy as this crisis continues.  Cyber-attacks have intensified
0 Comments
While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded. As a result, investors can be taken on a wild ride. Nevertheless, biotech penny stocks – or more generally
0 Comments